- Home
- PHUN vs CTSO Comparison
PHUN vs CTSO Comparison
Compare PHUN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | CTSO |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 49.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHUN | CTSO |
|---|---|---|
| Price | $2.03 | $0.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $7.25 | $5.38 |
| AVG Volume (30 Days) | ★ 186.6K | 129.8K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,357,000.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $11.93 |
| Revenue Next Year | $72.40 | $21.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $1.83 | $0.60 |
| 52 Week High | $6.29 | $1.61 |
Technical Indicators
Market Signals| Indicator | PHUN | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 48.68 |
| Support Level | $1.83 | $0.60 |
| Resistance Level | $2.13 | $0.85 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 37.50 | 60.00 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.